文献速递新发突发、热带与寄生虫病

TAK-003 登革热四价减毒活疫苗候选株的临床安全性经验

Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate.
PubMed 文献 · Clin Infect Dis · 2023-01-01

本文基于2项2期和3项3期双盲安慰剂对照试验的整合分析,评估TAK-003在4-60岁健康人群中的安全性。最常见的局部和全身不良事件为注射部位疼痛(TAK-003组43% vs 安慰剂组26%)和头痛(34% vs 30%)。严重不良事件在TAK-003组较少(6% vs 8%),未发现重要安全性风险,各年龄、性别和基线登革热血清状态亚组耐受性良好。

要点

  • 注射部位疼痛为最常见局部不良事件(TAK-003组43% vs 安慰剂组26%),多为轻度并于1-3天内缓解。
  • 严重不良事件TAK-003组6% vs 安慰剂组8%,5例疫苗相关严重不良事件中4例发生于安慰剂组。
  • 青少年和成人局部反应原性率高于儿童,基线血清状态和性别亚组间安全性无差异。

核心结论

  • 未发现重要安全性风险,TAK-003在4-60岁受种者中无论年龄、性别或基线登革热血清状态均耐受良好。

研究设计与样本

  • 整合分析2项2期和3项3期双盲、安慰剂对照临床试验中4-60岁健康受试者的安全性数据。
  • TAK-003组n=14 627,安慰剂组n=7167。
  • 安全性评估包括注射后反应原性、非征集性不良事件、严重不良事件和死亡,并按年龄组、基线血清状态和性别进行亚组分析。

主要发现

  • 最常见的局部和全身不良事件分别为注射部位疼痛(TAK-003组43% vs 安慰剂组26%)和头痛(TAK-003组34% vs 安慰剂组30%)。
  • 注射部位不良事件多为轻度,并在1-3天内缓解。
  • 非征集性不良事件和导致停药的不良事件在两组间发生频率相似。
  • 严重不良事件在TAK-003组较少(6% vs 安慰剂组8%)。
  • 5例疫苗相关严重不良事件(包括超敏反应、登革热和登革出血热)中4例发生于安慰剂组,未发现疫苗相关死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An unmet medical need remains for an effective dengue tetravalent vaccine that can be administered irrespective of previous dengue exposure. TAK-003, a dengue tetravalent vaccine, has demonstrated efficacy in an ongoing phase 3 trial in children and adolescents living in dengue-endemic areas, with an acceptable safety profile in both dengue-naive and dengue-exposed individuals. METHODS: Safety findings are presented herein from an integrated analysis of data for healthy 4-60-year-olds from two phase 2 and three phase 3 double-blind, placebo-controlled clinical trials of TAK-003 (TAK-003, n = 14 627; placebo, n = 7167). Safety evaluation included analyses of postinjection reactogenicity, unsolicited adverse events (AEs), serious AEs (SAEs), and deaths. Subgroup analyses were performed by age group, baseline serostatus, and gender. RESULTS: The most common local and systemic AEs were injection site pain (43% for TAK-003 and 26% for placebo) and headache (34% and 30%, respectively). Injection site AEs were mostly mild and resolved within 1-3 days. Unsolicited AEs and AEs leading to discontinuation occurred with similar frequency across both groups, while SAEs were fewer for TAK-003 recipients (6% vs 8% for placebo). Four of the 5 vaccine-related SAEs (which included hypersensitivity, dengue fever, and dengue hemorrhagic fever) occurred in the placebo group. No deaths were considered vaccine-related. Subgroup analyses showed no differences in safety by baseline serostatus or by gender, albeit analysis by age indicated greater local reactogenicity rates for adolescents (46% for TAK-003 and 28% for placebo) and adults (56% and 19%, respectively) than for children (37% and 25%, respectively). CONCLUSIONS: No important safety risks were identified, and TAK-003 was well tolerated irrespective of age, gender, or baseline dengue serostatus in recipients aged 4-60 years.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Patel SS, Rauscher M, Kudela M, et al. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate. Clin Infect Dis. 2023. PMID: 35639602. doi:10.1093/cid/ciac418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。